A recent report published by
Infinium Global Research on post operative nausea and vomiting market provides an in-depth analysis of segments and sub-segments in the global as well as
regional post operative nausea and vomiting market. The study also highlights
the impact of drivers, restraints, and macro indicators on the global and
regional post operative nausea and vomiting market over the short term as well
as long term. The report is a comprehensive presentation of trends, forecast
and dollar values of the global post operative nausea and vomiting market. According
to the report, the global post operative nausea and vomiting market is
projected to grow at a CAGR of over 8% over the forecast period of 2022-2028.
Market
Insight
The global post operative nausea
and vomiting market size to grow from about USD 2200 million in 2022 to nearly USD 3600 million by 2028, at a CAGR
of over 8% during the forecast period. Post operative nausea and vomiting are
uncomfortable for patients and can lead to more serious complications. It is an
enormous problem for patients recovering after surgery. About 30% of people
experience vomiting and 50% experience nausea. As many as 80% of high-risk
individuals may experience post operative nausea and vomiting.
Post operative nausea and vomiting
(PONV) are amongst the most frequently occurring complications in patients
undergoing surgery with general anesthesia. Nausea and vomiting are common and
distressing symptoms or side effects in medicine, surgery, and following
anesthesia. Generally, uncomplicated PONV rarely goes beyond 24 hours post operatively and problematic PONV however is more multifactorial in origin
and can be difficult to treat effectively. Patients at risk of this should be
identified by the anesthetist and may be given prophylactic anti-emetic
treatment. Post operative nausea and vomiting (PONV) are one of the complex and
significant problems in anesthesia practice, with the growing trend toward
ambulatory and daycare surgeries. A growing adoption rate of combination
therapies as well as non-pharmacological treatment modes is driving the growth
of the market. Moreover, the surge in funding is expected to boost the growth
of post operative nausea and vomiting (PONV) market during the forecast period.
However, strict regulatory approvals and high health care expenditure is
affecting the growth of the market during the forecast period. Moreover, the
launch of newer therapies is anticipated to provide a significant growth
opportunity for the market.
Nausea and vomiting (PONV) are
frequent after general anesthesia and enhance the risk of infection to
health professionals and patient discomfort. The Medication for PONV
treatment may present adverse effects on patients with COVID-19. Antiemetics
have gained an active position in the COVID-19 pandemic as a medical approach
to suppressing SARS-CoV-2-induced nausea and vomiting and balancing side
effects from medications in use. Additionally, these antiemetics may even be
more important in the field of emergency surgical patients with COVID-19 who
might be treated more likely with open surgery and therefore more prone to
nausea and vomiting.
North America holds the largest
market share in the post operative nausea and vomiting (PONV) market. Healthcare remuneration in the United States of America (USA) has transitioned
from volume-based systems to value-based systems. This means healthcare
institutions are financially incentivized to provide care according to
evidence-based best practices. Furthermore, a large presence of local
pharmaceutical companies in this region is expected to propel market growth in
the North American region. Moreover, Asia Pacific is expected to grow with a
healthy CAGR. A growing number of patients undergoing surgical procedures and
an increase in compliance with pharmacologic and non-pharmacologic treatments are
attributing to the growth of the market in this region.
Segment
Covered
The report on the global post operative
nausea and vomiting market covers segments such as treatment type, and
distribution channel. On the basis of treatment type, the sub-markets include
serotonin antagonists, dopamine antagonists, NK-1 receptor antagonists, and
non-pharmacological treatment. On the basis of distribution channel, the
sub-markets include hospital pharmacies, and retail pharmacies & drug
stores.
Companies
Profiled:
The report provides profiles of
the companies in the market such as Novartis AG, Acacia Pharma, Hoffmann-La
Roche AG, Camurus AB, Sanofi S.A, Helsinn Holding S.A, Eisai Corporation, Merck
and Co, and GlaxoSmithKline Corporation.
Report
Highlights:
The report provides deep insights
into demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of post operative nausea and vomiting market. Moreover, the study
highlights current market trends and provides forecast from 2022-2028. We also
have highlighted future trends in the market that will affect the demand during
the forecast period. Moreover, the competitive analysis given in each regional
market brings insight into the market share of the leading players.
Please Choose One of them.